Activation of the SIRT1/p66shc antiapoptosis pathway via carnosic acid-induced inhibition of MIR-34a protects rats against nonalcoholic fatty liver disease

Cell Death and Disease

Volumn 6, Issue 7, 2015, Pages

  Shan, W ^a   Gao, L ^a   Zeng, W ^a   Hu, Y ^a   Wang, G ^a   Li, M ^a   Zhou, J ^a   Ma, X ^a   Tian, X ^a   Yao, J ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CARNOSIC ACID; CASPASE 3; CASPASE 9; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; MANGANESE SUPEROXIDE DISMUTASE; MICRORNA 34A; PALMITIC ACID; PROTEIN BCL XL; SIRTUIN 1; SUPEROXIDE DISMUTASE; TRIACYLGLYCEROL; ABIETANE DERIVATIVE; AMINOTRANSFERASE; ANTIOXIDANT; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MICRORNA; MIRN34 MICRORNA, RAT; PROTECTIVE AGENT; SHC SIGNALING ADAPTOR PROTEIN; SHC TRANSFORMING PROTEIN 1; SHC1 PROTEIN, RAT; SIRT1 PROTEIN, RAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; GENE EXPRESSION; HUMAN; HUMAN CELL; LIPID DIET; LIPID PEROXIDATION; LIVER CELL; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRIACYLGLYCEROL BLOOD LEVEL; UPREGULATION; ADVERSE EFFECTS; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; ANTIOXIDANTS; APOPTOSIS; CASPASE 3; DIET, HIGH-FAT; DITERPENES, ABIETANE; GENE EXPRESSION REGULATION; HEPATOCYTES; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MALE; MICRORNAS; NON-ALCOHOLIC FATTY LIVER DISEASE; PALMITIC ACID; PROTECTIVE AGENTS; RATS; RATS, SPRAGUE-DAWLEY; SHC SIGNALING ADAPTOR PROTEINS; SIGNAL TRANSDUCTION; SIRTUIN 1; SRC HOMOLOGY 2 DOMAIN-CONTAINING, TRANSFORMING PROTEIN 1; SUPEROXIDE DISMUTASE; TRANSAMINASES; TRIGLYCERIDES;

EID: 84952647397     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2015.196     Document Type: Article

References (47)

1. Millic S, Lulic D, Simac D. Non-alcoholic fatty liver disease and obesity: Biochemical, metabolic and clinical presentations. World J Gastroenterol 2014; 20: 9330-9337.
2. Berlanga A, Guiu-Jurado E, Porras JA, Auguet T. Molecular pathways in non-alcoholic fatty liver disease. Clin Exp Gastroenterol 2014; 7: 221-239.
3. Cheung O, Sanyal AJ. Recent advances in nonalcoholic fatty liver disease. Curr Opin Gastroenterol 2010; 26: 202-208.
4. Derdak Z, Lang CH, Villegas KA, Tong M, Mark NM, de la Monte SM et al. Activation of p53 enhances apoptosis and insulin resistance in a rat model of alcoholic liver disease. J Hepatol 2011; 54: 164-172.
5. Wang K. Molecular mechanisms of hepatic apoptosis. Cell Death Dis 2014; 5: e996.
6. Schuppan D, Schattenberg JM. Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches. J Gastroenteral Hepatol 2013; 28: 68-76.
7. Jadeja R, Derkar RV, Narmmi S. Herbal medicines for the treatment of nonalcoholic steatohepatitis: current scenario and future prospects. Evid Based Complement Alternat Med 2014; 2014: 648308.
8. Rašković A, Milanović I, Pavlović N, Ćebović T, Vukmirović S, Mikov M et al. Antioxidant activity of rosemary (Rosmarinus officinalis L.) essential oil and its hepatoprotective potential. BMC Complement Altern Med 2014; 14: 225.
9. Jordán MJ, Lax V, Rota MC, Lorán S, Sotomayor JA. Relevance of carnosic acid, carnosol, and rosmarinic acid concentrations in the in vitro antioxidant and antimicrobial activities of Rosmarinus officinalis (L.) methanolic extracts. J Agric Food Chem 2012; 60: 9603-9608.
10. Park MY, Mun ST. Dietary carnosic acid suppresses hepatic steatosis formation via regulation of hepatic fatty acid metabolism in high-fat diet-fed mice. Nutr Res Pract 2013; 7: 294-301.
11. Petiwala SM, Berhe S, Li G, Puthenveetil AG, Rahman O, Nonn L et al. Rosemary (Rosmarinus officinalis) extract modulates CHOP/GADD153 to promote androgen receptor degradation and decreases xenograft tumor growth. PloS one 2014; 9: e89772.
12. Kar S, Palit S, Ball WB, Das PK. Carnosic acid modulates Akt/IKK/NF-κB signaling by PP2A and induces intrinsic and extrinsic pathway mediated apoptosis in human prostate carcinoma PC-3 cells. Apoptosis 2012; 17: 735-747.
13. Min KJ, Jung KJ, Kwon TK. Carnosic acid induces apoptosis through reactive oxygen species-mediated endoplasmic reticulum stress induction in human renal carcinoma caki cells. J Cancer Prev 2014; 19: 170-178.
14. Sahu BD, Putcha UK, Kuncha M, Rachamalla SS, Sistla R. Carnosic acid promotes myocardial antioxidant response and prevents isoproterenol-induced myocardial oxidative stress and apoptosis in mice. Mol Cell Biochem 2014; 394: 163-176.
15. Chen JH, Ou HP, Lin CY, Lin FJ, Wu CR, Chang SW, Tsai CW. Carnosic acid prevents 6-hydroxydopamine-induced cell death in SH-SY5Y cells via mediation of glutathione synthesis. Chem Res Toxicol 2012; 25: 1893-18901.
16. Sahu BD, Rentam KK, Putcha UK, Kuncha M, Veqi GM, Sistla R. Carnosic acid attenuates renal injury in an experimental model of rat cisplatin-induced nephrotoxicity. Food Chem Toxicol 2011; 49: 3090-3097.
17. Yan H, Jihong Y, Feng Z, Xiaomei X, Xiaohan Z, Guangzhi W et al. Sirtuin 1-mediated inhibition of p66shc expression alleviates liver ischemia/reperfusion injury. Crit Care Med 2014; 42: e373-e381.
18. Neilso JR, Sharp PA. Small RNA regulators of gene expression. Cell 2008; 134: 899-902.
19. Derdak Z, Villeqas KA, Harb R, Wu AM, Sousa A, Wands JR. Inhibition of p53 attenuates steatosis and liver injury in a mouse model of non-alcoholic fatty liver disease. J Hepatol 2013; 58: 785-791.
20. McDaniel K, Herrera L, Zhou T, Francis H, Han Y, Levine P et al. The functional role of microRNAs in alcoholic liver injury. J Cell Mol Med 2014; 18: 197-207.
21. Tomé-Carneiro J, Larrosa M, Yáñez-Gascón MJ. One-year supplementation with a grape extract containing resveratrol modulates inflammatory-related microRNAs and cytokines expression in peripheral blood mononuclear cells of type 2 diabetes and hypertensive patients with coronary artery disease. Pharmacol Res 2013; 72: 69-82.
22. Milenkovic D, Jude B, Morand C. miRNA as molecular target of polyphenols underlying their biological effects. Free Radic Biol Med 2013; 64: 40-51.
23. Egnatchik RA, Leamy AK, Jacobson DA, Shiota M, Young JD. ER calcium release promotes mitochondrial dysfunction and hepatic cell lipotoxicity in response to palmitate overload. Mol Metab 2014; 3: 544-553.
24. Nassir F, Ibdah JA. Role of mitochodria in nonalcoholic fatty liver disease. Int J Mol Sci 2014; 15: 8713-8742.
25. Migliaccio E, Giorgio M, Mele S, Pelicci G, Reboldi P, Pandolfi PP et al. The p66shc adaptor protein controls oxidative stress response and life span in mammals. Nature 1999; 402: 309-313.
26. Tomita K, Teratani T, Suzuki T, Oshikawa T, Yokoyama H, Shimamura K et al. p53/p66Shc-mediated signaling contributes to the progression of non-alcoholic steatohepatitis in humans and mice. J Hepatol 2012; 57: 837-843.
27. Koch OR, Fusco S, Ranieri SC, Maulucci G, Palozza P, Larocca LM et al. Role of the life span determinant P66(shcA) in ethanol-induced liver damage. Lab Invest 2008; 88: 750-760.
28. Yamakuchi M, Ferlito M, Lowenstein CJ. miR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci USA 2008; 105: 13421-13426.
29. Herbert KJ, Cook AL, Snow ET. SIRT1 inhibition restores apoptotic sensitivity in p53-mutated human keratinocytes. Toxicol Appl Pharmacol 2014; 277: 288-297.
30. Ferreira DM, Afonso MB, Rodrigues PM, Simão AL, Pereira DM, Borralho PM et al. c-Jun N-terminal kinase 1/c-Jun activation of the p53/microRNA 34a/sirtuin 1 pathway contributes to apoptosis induced by deoxycholic acid in rat liver. Mol Cell Biol 2014; 34: 1100-1120.
31. Ren T, Huang C, Cheng M. Dietary blueberry and bifidobacteria attenuate nonalcoholic fatty liver disease in rats by affecting SIRT1 mediated signaling pathway. Oxid Med Cell Longev 2014; 2014: 469059.
32. Castro RE, Ferreira DM, Afonso MB, Borralho PM, Machado MV, Cortez-Pinto H, Rodrigues CM. miR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease. J Hepatol 2013; 58: 119-125.
33. Park MY, Sung MK. Carnosic acid attenuates obesity-induced glucose intolerance and hepatic fat accumulation by modulating genes of lipid metabolism in C57BL/6J-ob/ob mice. J Sci Food Agric 2015; 95: 828-835.
34. Tai J, Cheung S, Wu M, Hasman D. Antiproliferation effect of Rosemary (Rosmarinus officinalis) on human ovarian cancer cells in vitro. Phytomedicine 2012; 19: 436-443.
35. Petiwala SM, Puthenveetil AG, Johnson JJ. Polyphenols from the Mediterranean herb rosemary (Rosmarinus officinalis) for prostate cancer. Front Pharmacol 2013; 4: 29.
36. Gerhard GS, Distefana JK. Micro RNAs in the development of non-alcoholic fatty liver disease. World J Hepatol 2015; 7: 226-234.
37. Choi SE, Fu T, Seok S, Kim DH, Yu E, Lee KW et al. Elevated microRNA-34a in obesity reduces NAD+ levels and SIRT1 activity by directly targeting NAMPT. Aging Cell 2013; 12: 1062-1072.
38. Cermelli S, Ruggieri A, Marrero JA, Ioannou GN, Beretta L. Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS One 2011; 6: e23937.
39. Purushotham A, Schug TT, Xu Q, Surapureddi S, Guo X, Li X. Hepatocytespecific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab 2009; 9: 327-338.
40. Mariani S, Fiore D, Basciani S, Persichetti A, Contini S, Lubrano C. Plasma levels of SIRT1 associate with non-alcoholic fatty liver disease in obese patients. Endocrine 2014; e-pub ahead of print 31 October 2014.
41. Xu F, Li Z, Zheng X, Liu H, Liang H, Xu H et al. SIRT1 mediates the effect of GLP-1 receptor agonist exenatide on ameliorating hepatic steatosis. Diabetes 2014; 63: 3637-3646.
42. Zhou S, Chen HZ, Wan YZ, Zhang QJ, Wei YS, Huang S et al. Repression of P66Shc expression by SIRT1 contributes to the prevention of hyperglycemia-induced endothelial dysfunction. Circ Res 2011; 109: 639-648.
43. Xu X, Hu Y, Zhai X, Lin M, Chen Z, Tian X et al. Salvianolic acid A preconditioning confers protection against concanavalin-A-induced liver injury through SIRT1-mediated repression of p66shc in mice. Toxicol Appl Pharmacol 2013; 273: 68-76.
44. Kucera O, Cervinkova Z. Experimental models of non-alcoholic fatty liver disease in rats. World J Gastroenterol 2014; 20: 8364-8376.
45. Li S, Liao X, Meng F, Wang Y, Sun Z, Guo F et al. Therapeutic role of ursolic acid on ameliorating hepatic steatosis and improving metabolic disorders in high-fat diet-induced non-alcoholic fatty liver disease rats. PLoS One 2014; 9: e86724.
46. Wang JW, Wan XY, Zhu HT, Lu C, Yu WL, Yu CH et al. Lipotoxic effect of p21 on free fatty acid-induced steatosis in L02 cells. PLoS One 2014; 9: e96124.
47. Shan X, Miao Y, Fan R, Song C, Wu G, Wan Z et al. Suppression of Grb2 expression improved hepatic steatosis, oxidative stress, and apoptosis induced by palmitic acid in vitro partly through insulin signaling alteration. In Vitro Cell Dev Biol Anim 2013; 49: 576-582.